Classification of diabetes

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 12-19

  De Faria Maraschin, Jorge ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CLOZAPINE; GLUCOCORTICOID; HLA ANTIGEN; INSULIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PENTAMIDINE; PROTEINASE INHIBITOR; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ARTICLE; AUTOIMMUNE DISEASE; COXSACKIE VIRUS INFECTION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE CLASSIFICATION; EXERCISE; GENETIC DISORDER; GENETIC PREDISPOSITION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CARCINOMA; PREGNANCY DIABETES MELLITUS; RUBELLA; CLASSIFICATION; ENDOCRINOLOGY; MEDICAL SOCIETY; NOMENCLATURE; PATHOPHYSIOLOGY; REVIEW; STANDARD;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; HUMANS; SOCIETIES, MEDICAL; TERMINOLOGY AS TOPIC;

EID: 84907817657     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: None     Document Type: Article

References (41)

1. Maraschin JF, Murussi N, Witter V et al. Diabetes mellitus classi fication. Arq Bras Cardiol 2010; 95:40-6.
2. Report of the Expert Committee on the Diagnosis and Class ification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-97.
3. King GL, Brownlee M. The cellular and molecular mechanism of diabetic complications. Endocrinol Metab Clin North Am 1996; 25:255-70.
4. King H, Aubert RE, Herman WHo Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
5. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53.
8. Gerstein HC, Miller ME, Byington RP. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
9. Patel A, MacMahon S, Chalmers J. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-72.
10. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-39.
11. Nathan DM, Cleary PA, Backlund JY. Diabetes Control and Complications Trial/Epidemi ology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med 2005; 353:2643-53.
12. Holman RR, Paul SK, Bethel MA et al. 10-Year Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-89.
13. Skyler JS, Bergenstal R, Bonow RO et al. Position Statement. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific statement of the American College of Cardiology; Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-92.
14. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(suppl 1):S11-61.
15. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and others categories of glucose intolerance. Diabetes 1979; 28:1039-57.
16. Alberti KGMM, Zimmet PZ. Definition, diagnosis, and classificationof diabetesmellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provision report of a WHO consultation. Diabet Med 1998; 15:539-53.
17. Genuth S, Alberti KG, Bennett P et al. Follow-Up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 2003; 26:3160-7.
18. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva: WHO; 2006.
19. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(suppl 1):S62-9.
20. Karvonen M, Tuomilehto J, Libman I, La Porte R. A review of the recent epidemiologicaldata on the worldwide incidence of type 1 diabetes mellitus. Diabetologia 1993; 36:883-92.
21. Buzzetti R, Quattrocchi C, Nistico L. Dissecting the genetics of type 1 diabetes: Relevance for familial clustering and differences in incidence. Diabetes Metab Rev 1998; 14:111-28.
22. Dahlquist G. The aetiology of type 1 diabetes:anepidemiological perspective. Acta Paediatr Suppl 1998;425:5-10.
23. Scott FW, Norris J, Hubert K. Milk and type 1 diabetes: examining the evidence and broadering the focus. Diabetes Care 1996; 19:379-83.
24. Zimmet PZ, Tuomi T, Mackay IR et al. Latent Autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in the diagnosis and prediction of insulin dependency. Diabet Med 1994; 11:299-303.
25. McLarty DG, Athaide I, Botazzo G et al. Islet cell antibodies arenot specifically associated with insulin-dependent diabetes in rural Tanzanian Africans. Diabetes Res Clin Pract 1990; 9:219-24.
26. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev 2008; 29:292-302.
27. Rudenski AS, Hadden D, Atkinsom A et al. Natural history of panc reatic islet β-cell function in type 2 diabetes mellitus studied over six years by homeo stasis model assessment. Diabet Med 1988; 5:36-41.
28. Mokdad AH, Bowman BA, Ford ES et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195-200.
29. Barnett AH, Eff C, Leslie R et al. Diabetes in identical twins: a study of 200 pairs. Diabetologia 1981; 20:87-93.
30. Knowler WC, Saad M, Pettitt D et al. Determ inants of diabetes mell itus in the pima Indians. Diabetes Care 1993; 16:216-27.
31. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971-80.
32. Velho G, Froguel P. Maturity-onset diabetes of the young (MODY), MODY genes and non-insulin dependet diabetes mellitus. Diabetes Metab 1997; 23:34-7.
33. Haneda M, Polonsky K, Bergenstal R et al. Familial Hyperin sulinemia due to structurally abnormal insulin: Definition of an emerging new clinical syndrome. N Engl J Med 1984; 310: 1288-94.
34. Tritos NA, Mantzocos CS. Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83:3025-30.
35. Gullo L, Pezzilli R, Moselli-Labate A et al. Diabetes and the risk of pancre atic cancer. N Engl J Med 1994; 331:81-4.
36. Moran A, Doherty L, Wang X et al. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998; 133:10-7; http://dx.doi.org/10.1016/S0022-3476(98)70171-4.
37. Pandit MK, Burke J, Gustafson A et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 118:529-39.
38. Forrest JM, Menser M, Burgess JA. High frequency of diabetes mellitus in young patients with congenital rubella. Lancet 1971; 2:332-4.
39. King ML, Bidwell D, Chihk A et al. Coxsackie-B-virus-specific Ig M responses in children with insulin-dependent (juvenile-onset: type 1) diabetes mellitus. Lancet 1983; 1:1397-9.
40. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care 2010; 33:676-682.
41. Carr S: Screening for gestational diabetes mellitus. Diabetes Care 1998; 21: B14-B18.